Zura Bio Ltd
Business
Zura Bio Limited is a clinical-stage biotechnology company developing novel monoclonal antibodies and bispecific antibodies for autoimmune and inflammatory diseases. The company's pipeline comprises three in-licensed product candidates: tibulizumab (a bispecific antibody targeting IL-17A and BAFF), crebankitug (targeting IL-7 receptor alpha), and torudokimab (targeting IL-33), currently evaluated in Phase 2 trials for hidradenitis suppurativa, diffuse cutaneous systemic sclerosis, and other immune-mediated conditions. Zura outsources manufacturing to contract manufacturers and operates through license agreements with Eli Lilly and Pfizer for development and commercialization rights.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 42 | 24 | 44 | 24 | |
| General and administrative | 33 | 31 | 19 | 3 | |
| Total operating expenses | 75 | 55 | 63 | 27 | |
| Loss from operations | −75 | −55 | −63 | −27 | |
| Interest income | −6 | −8 | −2 | −8,000 | |
| Change in fair value of private placement warrants | — | 5 | −724,000 | −4 | |
| Other income, net | −260,000 | −28,000 | −17,000 | — | |
| Total other income, net | −7 | −3 | −2 | 6 | |
| Loss before income taxes | −69 | −52 | −61 | −27 | |
| Income tax benefit | — | — | 0 | — | |
| Net loss | −69 | −52 | −60 | −26 | |
| Adjustment of redeemable noncontrolling interest | 831,000 | 7 | — | — | |
| Accretion of redeemable noncontrolling interest to redemption value | 5 | — | −7 | −7 | |
| Deemed dividend on extinguishment of noncontrolling interest and redeemable noncontrolling interest | −36 | — | — | — | |
| Net loss attributable to Class A Ordinary Shareholders of Zura | −99 | −45 | −69 | −32 | |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in dollars per share) | −1.06 | −0.6 | −2.09 | −141.97 | |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in dollars per share) | −1.06 | −0.6 | −2.09 | −141.97 | |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic (in shares) | 94 | 75 | 33 | 228,148 | |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, diluted (in shares) | 94 | 75 | 33 | 228,148 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 109 | 176 | 100 | 13,785 | 729,223 | |
| Prepaid expenses and other current assets | 3 | 2 | 1 | — | — | |
| Total current assets | 112 | 179 | 101 | 2 | 1 | |
| Property and equipment, net | 126,000 | 91,000 | — | — | — | |
| Other assets | 2 | 698,000 | — | — | — | |
| Total assets | 114 | 180 | 101 | 5 | 141 | |
| Accounts payable and accrued expenses | 12 | 20 | 20 | 4 | — | |
| Total current liabilities | 12 | 20 | 20 | 15 | 272,292 | |
| Total liabilities | 12 | 20 | 21 | 15 | 10 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Redeemable noncontrolling interest | — | 12 | 19 | 10 | — | |
| Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 73,680,710 and 65,297,530 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 7,000 | 7,000 | 4,000 | — | — | |
| Additional paid-in capital | 326 | 303 | 163 | — | — | |
| Accumulated deficit | −225 | −156 | −104 | −32 | −9 | |
| Total Zura Bio Limited shareholders' equity | 102 | 147 | 59 | −32 | −9 | |
| Noncontrolling interest | — | 2 | 2 | 0 | — | |
| Total shareholders' equity | 102 | 148 | 61 | −32 | — | |
| Total liabilities, redeemable noncontrolling interest and shareholders' equity | 114 | 180 | 101 | 5 | 141 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss before redeemable noncontrolling interest | −69 | −52 | −61 | −27 | |
| Share-based compensation expense | 12 | 17 | 7 | 334,000 | |
| Depreciation and amortization | 49,000 | 9,000 | — | — | |
| Foreign exchange transaction gain | 84,000 | −27,000 | −17,000 | 23,000 | |
| Gain on extinguishment of BAFFX17 liability | −5 | — | — | — | |
| Other non-cash items, net | 4,000 | — | — | — | |
| Prepaid expenses and other current assets | −657,000 | −1 | −828,000 | −209,000 | |
| Other assets | −814,000 | −698,000 | — | — | |
| Accounts payable and accrued expenses | −2 | 4 | 6 | 4 | |
| Net cash used in operating activities | −65 | −28 | −15 | −1 | |
| Purchase of fixed assets | −113,000 | −75,000 | — | — | |
| Purchase of research and development license | — | −5 | −8 | −12 | |
| Net cash used in investing activities | −113,000 | −5 | −8 | −12 | |
| ATM transaction costs | — | −626,000 | 4 | — | |
| Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants | 3,000 | — | — | — | |
| Proceeds from exercise of stock options | 107,000 | — | — | — | |
| Restricted stock units withheld to pay employee withholding taxes | −41,000 | −318,000 | — | — | |
| Consideration paid for Athanor Agreement | −7 | — | — | — | |
| Net cash provided by (used in) financing activities | −2 | 110 | 121 | 15 | |
| Net increase in cash and cash equivalents | −67 | 77 | 98 | 2 | |
| Issuance of Class A Ordinary Shares in exchange for private placement warrants | — | 6 | — | 3 | |
| Issuance of shares in conjunction with Athanor agreement | 46 | — | — | — | |
| Adjustments to redeemable noncontrolling interest | — | 7 | — | — | |
| Purchase of property and equipment included in accounts payable and accrued expenses | — | 25,000 | — | — | |
| Extinguishment of noncontrolling interest and redeemable noncontrolling interest | 18 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Zura Bio Ltd's CIK number?
Zura Bio Ltd's SEC CIK number is 0001855644 (1855644). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Zura Bio Ltd's SEC filings?
All of Zura Bio Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Zura Bio Ltd last report earnings?
Zura Bio Ltd (ZURA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031701). This is Zura Bio Ltd's most recent earnings filing of record — not a forecast of its next earnings date.
What is Zura Bio Ltd's most recent earnings 8-K?
Zura Bio Ltd's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-031701. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Zura Bio Ltd's latest earnings 8-K →
Look up any company's CIK number →